Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 18/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | HBB | P68871 | 2/20 | 1.00 |
| ▸ | CASP1 | P29466 | 1/20 | 1.00 |
| ▸ | CASP7 | P55210 | 1/20 | 1.00 |
| ▸ | GLA | P06280 | 3/20 | 0.80 |
| ▸ | TP53 | P04637 | 2/20 | 0.80 |
| ▸ | HPGD | P15428 | 2/20 | 0.80 |
| ▸ | STAT6 | P42226 | 1/20 | 0.80 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.80 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.80 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.80 |
| ▸ | GMNN | O75496 | 1/20 | 0.80 |
| ▸ | LMNA | P02545 | 1/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydroxycamptothecin SCHEMBL9384413 | 1.00 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| Hydroxycamptothecin SCHEMBL29929278 | 1.00 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| Hydroxycamptothecin SCHEMBL25875 | 1.00 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| Hydroxycamptothecin SCHEMBL27713853 | 0.99 | TOP1 (0.98) | TOP1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| Hydroxycamptothecin SCHEMBL27638187 | 0.99 | TOP1 (0.98) | TOP1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| Hydroxycamptothecin SCHEMBL26683387 | 0.99 | TOP1 (0.98) | TOP1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| Hydroxycamptothecin SCHEMBL30872708 | 0.99 | TOP1 (0.98) | TOP1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| Hydroxycamptothecin SCHEMBL28836816 | 0.99 | TOP1 (0.98) | TOP1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| Hydroxycamptothecin SCHEMBL30426602 | 0.99 | TOP1 (0.98) | TOP1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| Hydroxycamptothecin SCHEMBL27466705 | 0.99 | TOP1 (0.98) | TOP1MEN1KMT2ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 496 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026086871-A1 | ANTI-AGEING COMPOUNDS, USES THEREFOR, METHOD FOR IDENTIFYING, AND COMPOSITIONS CONTAINING | Centre for Translational Stem Cell Biology Limited (CN) | 2026-04-30 | — | — | WO | claimed |
| US-20260120870-A1 | ARTIFICIAL INTELLIGENCE-BASED INFORMATION PROVISION METHOD FOR DIAGNOSING LUNG CANCER BY USING BIOMARKER FOR LUNG CANCER DIAGNOSIS AND CLINICAL INFORMATION OF TEST SUBJECT | INNOBATION BIO CO LTD (KR) | 2026-04-30 | — | — | US | claimed |
| EP-4687999-A1 | TROP2 CONJUGATED BIOLOGICAL MOLECULES, PHARMACEUTICAL COMPOSITIONS AND METHODS | OBI Pharma, Inc. (TW) | 2026-02-11 | — | — | EP | claimed |
| US-12493041-B2 | Apparatus for diagnosing solid cancers and method for providing information on solid cancer diagnosis | INNOBATION BIO CO., LTD. (KR) | 2025-12-09 | — | — | US | claimed |
| EP-4640238-A1 | THERAPEUTIC AGENT FOR PULMONARY DISEASE, HEPATIC DISEASE OR RENAL DISEASE, WHICH CONTAINS PGAM-CHK1 BINDING INHIBITOR | Kyoto University (JP) | 2025-10-29 | — | — | EP | claimed |
| EP-4597100-A1 | ARTIFICIAL INTELLIGENCE-BASED INFORMATION PROVISION METHOD FOR DIAGNOSING LUNG CANCER BY USING BIOMARKER FOR LUNG CANCER DIAGNOSIS AND CLINICAL INFORMATION OF TEST SUBJECT | Innobation Bio Co., Ltd. (KR) | 2025-08-06 | — | — | EP | claimed |
| US-20250003952-A1 | SENOLYTIC DRUG SCREENING METHOD AND SENOLYTIC DRUG | KYOTO UNIVERSITY (JP) | 2025-01-02 | — | — | US | claimed |
| EP-4450070-A1 | CRF1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA | NEUROCRINE BIOSCIENCES, INC. (US) | 2024-10-23 | — | — | EP | claimed |
| WO-2024206480-A1 | TROP2 CONJUGATED BIOLOGICAL MOLECULES, PHARMACEUTICAL COMPOSITIONS AND METHODS | O B I PHARMA, INC. (TW) | 2024-10-03 | — | — | WO | claimed |
| CN-118530246-A | Synthesis and antitumor application of 10-alkylated 5-spiro camptothecin derivatives | 遵义医科大学 | 2024-08-23 | — | — | CN | claimed |
| WO-2023091944-A1 | COMBINATION THERAPY WITH ANTI-TROP-2 ANTIBODIES AND PARP INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2023-05-25 | — | — | WO | claimed |
| US-20230130925-A1 | METHODS TO PREVENT, AMELIORATE AND TREAT COMPLICATIONS FROM VIRAL INFECTIONS | ANGELES THERAPEUTICS, INC. | 2023-04-27 | — | — | US | claimed |
| WO-2023038027-A1 | SENOLYTIC DRUG SCREENING METHOD AND SENOLYTIC DRUG | 国立大学法人京都大学 | 2023-03-16 | — | — | WO | claimed |
| CN-108884438-B | Method for producing hepatocyte | 拜奥拉米那公司 | 2022-12-23 | — | — | CN | claimed |
| US-20220349895-A1 | APPARATUS FOR DIAGNOSING SOLID CANCERS AND METHOD FOR PROVIDING INFORMATION ON SOLID CANCER DIAGNOSIS | INNOBATION BIO CO., LTD. (KR) | 2022-11-03 | — | — | US | claimed |
| WO-2022174058-A1 | THIOPHOSPHOPEPTIDES FOR ULTRAFAST TARGETING OF THE GOLGI APPARATUS | BRANDEIS UNIVERSITY (US) | 2022-08-18 | — | — | WO | claimed |
| US-20220227700-A1 | HDAC3 CATALYTIC INHIBITOR DEVELOPMENT AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | 2022-07-21 | — | — | US | claimed |
| EP-4027139-A2 | APPARATUS FOR DIAGNOSING SOLID CANCERS AND METHOD FOR PROVIDING INFORMATION ON SOLID CANCER DIAGNOSIS | Innobation Bio Co., Ltd. (KR) | 2022-07-13 | — | — | EP | claimed |
| US-20220193229-A1 | NUCLEIC ACID STABILIZING SOLUTION FOR VACCINES, THERAPY, DIAGNOSTICS, STORAGE, AND TRANSPORT | Daykin Molecular Systems, LLC | 2022-06-23 | — | — | US | claimed |
| WO-2022120490-A1 | CYTOCHROME P450 MONOOXYGENASES AND USES THEREOF | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2022-06-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260120870-A1 | ARTIFICIAL INTELLIGENCE-BASED INFORMATION PROVISION METHOD FOR DIAGNOSING LUNG CANCER BY USING BIOMARKER FOR LUNG CANCER DIAGNOSIS AND CLINICAL INFORMATION OF TEST SUBJECT | KYNU, CPT2, CPT1A | TOP1 3385/4885MEN1 1628/4885KMT2A 564/4885 |
| US-20220227700-A1 | HDAC3 CATALYTIC INHIBITOR DEVELOPMENT AND USES THEREOF | HDAC3, HDAC1, HDAC11 | TOP1 3352/4885MEN1 4572/4885KMT2A 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.